Mmbg Investment Advisors CO. Sells 1,910 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mmbg Investment Advisors CO. lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,591 shares of the medical research company's stock after selling 1,910 shares during the quarter. Thermo Fisher Scientific accounts for about 0.7% of Mmbg Investment Advisors CO.'s investment portfolio, making the stock its 29th biggest position. Mmbg Investment Advisors CO.'s holdings in Thermo Fisher Scientific were worth $6,271,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Citizens National Bank Trust Department raised its holdings in shares of Thermo Fisher Scientific by 4.0% in the 1st quarter. Citizens National Bank Trust Department now owns 4,883 shares of the medical research company's stock worth $2,430,000 after buying an additional 188 shares in the last quarter. Avidian Wealth Enterprises LLC boosted its stake in shares of Thermo Fisher Scientific by 16.6% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,321 shares of the medical research company's stock valued at $657,000 after purchasing an additional 188 shares in the last quarter. Root Financial Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 5.0% in the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after purchasing an additional 24 shares during the last quarter. McGuire Investment Group LLC increased its position in shares of Thermo Fisher Scientific by 2.3% during the 1st quarter. McGuire Investment Group LLC now owns 33,177 shares of the medical research company's stock worth $16,509,000 after purchasing an additional 745 shares in the last quarter. Finally, Goodman Advisory Group LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at about $233,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 0.6%

NYSE TMO traded down $2.45 on Monday, reaching $405.83. The company had a trading volume of 3,919,130 shares, compared to its average volume of 1,959,714. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The stock has a market cap of $153.20 billion, a price-to-earnings ratio of 23.80, a PEG ratio of 2.17 and a beta of 0.78. The stock's 50 day moving average is $409.74 and its 200-day moving average is $482.94.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the company posted $5.11 EPS. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

Several research firms have recently weighed in on TMO. Scotiabank dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Finally, Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.